Indications / MP1032 Pipeline

MP1032 Pipeline - Initial Focus on Orphan Diseases

News

MetrioPharm Announces Changes to its Board of Directors - 2025-Sep-04

Dr. Stephan Rietiker and Dr. Harald Fricke have stepped down with immediate effect. Jörg Gruber appointed as new Chairman of the Board of Directors.

» more

Please find our corporate slide-deck as download here:
» MetrioPharm corporate slide-deck

The iMPact project is one of six initiatives selected by the European Commission to work on drug candidates for the treatment of SARS-CoV-2. The project includes the conduct of a Phase II clinical trial with MetrioPharm's lead compound MP1032 against COVID-19.
» Find out more in the iMPact project film

Navigation

Home
About us
Technology
Pipeline
Investors
Press
Contact

Social

  

Newsletter

Subscribe to our press releases with the
MetrioPharm PR newsletter

Investors can subscribe to our quaterly corporate information with the
MetrioPharm IR newsletter

Switzerland (HQ)

MetrioPharm AG

Europaallee 41
8004 Zurich

Germany (R&D)

MetrioPharm Deutschland GmbH

Franklinstrasse 28/29
10587 Berlin

Imprint
Privacy policy (We don’t collect cookies)
Sitemap